Coverage & Financial Assistance.
Medicare covers serial NavDx® testing for surveillance of recurrence in patients with a history of documented HPV-driven oropharyngeal or anal cancer. The NavDx test is also covered by many commercial health insurance companies, and we are continually pursuing and gaining coverage to ensure patients have access to testing.
Naveris is committed to ensuring that NavDx testing is accessible to patients by providing support services, as well as financial assistance to those who qualify. Our Billing Team works with patients so that cost is not a barrier to testing.
